Curexo Inc. (060280.KQ)
KRW 9030.0
(1.46%)
KRW 9030.0
(1.46%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.13 Billion KRW | 4.22% |
| 2022 | 1.08 Billion KRW | 153.28% |
| 2021 | -2.04 Billion KRW | -602.01% |
| 2020 | 407.34 Million KRW | 109.44% |
| 2019 | -4.31 Billion KRW | 9.39% |
| 2018 | -4.76 Billion KRW | -955.89% |
| 2017 | 556.42 Million KRW | 101.37% |
| 2016 | -40.6 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.64 Billion KRW | -111.8% |
| 2024 Q2 | -1.28 Billion KRW | 21.79% |
| 2023 Q1 | 1.15 Billion KRW | 82.7% |
| 2023 Q2 | 1.15 Billion KRW | -0.78% |
| 2023 Q3 | -397.32 Million KRW | -134.54% |
| 2023 Q4 | -776.63 Million KRW | -95.47% |
| 2023 FY | 1.13 Billion KRW | 4.22% |
| 2022 Q2 | -434.69 Million KRW | -459.35% |
| 2022 FY | 1.08 Billion KRW | 153.28% |
| 2022 Q4 | 634.48 Million KRW | -17.46% |
| 2022 Q3 | 768.74 Million KRW | 276.85% |
| 2022 Q1 | 120.96 Million KRW | -55.5% |
| 2021 FY | -2.04 Billion KRW | -602.01% |
| 2021 Q4 | 271.84 Million KRW | 132.0% |
| 2021 Q3 | -849.55 Million KRW | 0.0% |
| 2020 FY | 407.34 Million KRW | 109.44% |
| 2019 FY | -4.31 Billion KRW | 9.39% |
| 2018 FY | -4.76 Billion KRW | -955.89% |
| 2017 FY | 556.42 Million KRW | 101.37% |
| 2016 FY | -40.6 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Osang Healthcare Co.,Ltd | 142.82 Billion KRW | 99.205% |
| InBody Co.,Ltd | 44.46 Billion KRW | 97.447% |
| Seegene, Inc. | -30 Billion KRW | 103.784% |
| i-SENS, Inc. | 10.92 Billion KRW | 89.611% |
| Ray Co., Ltd. | 6.11 Billion KRW | 81.442% |
| Gencurix Inc. | -12.37 Billion KRW | 109.175% |
| Sugentech Inc. | -22.74 Billion KRW | 104.993% |
| L&C Bio Co., Ltd | 6.66 Billion KRW | 82.969% |